BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target

BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.

The price target implies an upside of 167.1% from the Sep 15 close of $66.64.

Key takeaways from the analyst note

Strong Pipeline of Immunomodulatory Agents: Nektar Therapeutics is focused on developing a diverse portfolio of immunomodulatory therapies aimed at treating autoimmune diseases and cancer, which positions the company favorably for potential growth in the biopharmaceutical market.

Positive Phase 2 Trial Progress: The advancement of Nektar's lead program, rezpegaldesleukin, through Phase 2 trials for atopic dermatitis and alopecia areata, along with the initiation of multiple Phase 3 trials, indicates promising clinical progress that could lead to commercialization and revenue generation.

Explore more price target data and ratings for Nektar Therapeutics on the .

Disclaimer

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.